1 tracked superinvestor hold BRIDGEBIO PHARMA INC (BBIO), worth $879M combined, led by Andreas Halvorsen. Smart money is trimming BBIO as of the latest 13F filings.
Current price
$90.17
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3…
Market cap
$13.3B
P/E
-18.14
Div yield
—
Revenue YoY
—
Analyst target
—
Snapshot for context. For deep analysis use a stock screener — this page is about who owns it.
Superinvestors holding
1
tracked 13F / N-PORT funds
Combined value
$879M
disclosed long exposure
Tier-1 conviction
1
concentrated holders
Net this quarter
-1
0 buying · 1 selling
Smart money is net reducing BBIO: 1 funds trimmed versus 0 adding.
BRIDGEBIO PHARMA INC (BBIO) is held by 1 tracked funds worth $879M combined, 1 of them concentrated Tier-1 managers whose positions carry real conviction.
The largest position belongs to Andreas Halvorsen at 2.5% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
No tracked fund opened a new position this quarter; 0 added and 1 trimmed, a net reduction.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| Trimmed | 2.5% | $879M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
Which superinvestors own BBIO?
1 tracked funds hold BRIDGEBIO PHARMA INC (BBIO), the largest being Andreas Halvorsen (Viking Global Investors) at 2.5% of its 13F portfolio. 1 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling BBIO?
In the most recent 13F quarter, 0 tracked funds added or opened BBIO and 1 trimmed it.
How much BBIO do tracked funds hold?
Combined disclosed long exposure to BBIO across tracked superinvestors is $879M as of the Mar 2026 filings.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Mar 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.